A Pilot Study on the Activation of NOD2 Receptors in Preterm Infants by Lactobacillus Reuteri DSM17938
Latest Information Update: 24 Jan 2025
Price :
$35 *
At a glance
- Drugs Limosilactobacillus reuteri (Primary)
- Indications Bacterial infections; Gastrointestinal disorders
- Focus Therapeutic Use
- 24 Jan 2025 New trial record
- 22 Jan 2025 Status changed from not yet recruiting to completed.